In The News


January 8, 2024  |  Resilience

Resilience US, Inc. (formerly AstraZeneca), announced that it expects to create 274 full-time positions, generating $15 million in new annual payroll and retaining $27.2 million in existing payroll, as a result of its expansion project in West Chester Township.


Resilience is a biomanufacturing company specializing in the production of novel medicine. The proposed project includes the renovation of their current facility to operate more effectively for increased production staff to further their goal of implementing efficient manufacturing processes and supply chain solutions to improve access to their pharmaceuticals and therapies.


In mid-December 2023, the Tax Incentive Authority approved a 1.9%, 10-year Job Creation Tax Credit for this project.  The project will create 440 new jobs (274 direct hires, 166 contractor positions), retain 476 jobs, and include further development of Resilience’s West Chester biomanufacturing site.  The types of new employment opportunities encompass a wide variety of roles including manufacturing, engineering, quality control, IT and management.


The project includes a nearly $229 million capital investment.


“The significant investment by Resilience in West Chester will be impactful and sets the foundation for continued growth and investment in the advanced manufacturing and medical research arenas,” said West Chester Township Administrator Larry D. Burks. “West Chester Township is proud to be home to more than 3,500 exceptional and diverse companies. Together they create a vast network benefitting from West Chester’s location, access, workforce and commitment to building a resilient local economy. Our residents and the world will benefit from the work of Resilience and West Chester is honored to be selected as the site for this investment.”


Resilience purchased its West Chester site in January 2023 from AstraZeneca and has secured manufacturing agreements with several new customers.  To deliver on these contracts, while also preparing the facility to be commercially ready to deliver additional manufacturing services, significant capital investment and workforce recruitment is critical to its success.  Resilience is committed to bringing further development to the State, modernizing the facility and growing its West Chester workforce. 


AstraZeneca, on Trade Port Drive in West Chester Township, sold the 580,000 square-foot manufacturing facility to Resilience in early 2023 for $212 million.  Today, Resilience continues to produce the AstraZeneca drugs at the West Chester site as part of a multi-year supply agreement which included Resilience retaining existing employees. 


Katy Kanelopoulos, West Chester Township’s Economic Development Manager said, “I recently had the pleasure of meeting leadership while touring the Resilience plant and learning more about their vision. We are proud to be the home of such important and innovative work. West Chester has growing healthcare and manufacturing industries, proving us to be a top community for business in Ohio.  We celebrate this expansion and wholeheartedly support their mission of growth.”